Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR

A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m(2) vs. twice-weekly Kd 20/27 mg/m(2) based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm...

Descripción completa

Detalles Bibliográficos
Autores principales: Takezako, Naoki, Shibayama, Hirohiko, Handa, Hiroshi, Hagiwara, Shotaro, Ozaki, Shuji, Suzuki, Kenshi, Kosugi, Hiroshi, Ri, Masaki, Sugiura, Isamu, Choi, Ilseung, Miyamoto, Toshihiro, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547551/
https://www.ncbi.nlm.nih.gov/pubmed/33037990
http://dx.doi.org/10.1007/s12185-020-03013-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547551/
https://www.ncbi.nlm.nih.gov/pubmed/33037990
http://dx.doi.org/10.1007/s12185-020-03013-6

Ejemplares similares